Florida Cancer Specialists Collaborates with Oncology Leaders at FLASCO 2026 to Innovate Cancer Care

Florida Cancer Specialists Collaborates at FLASCO 2026

On April 10, 2026, Florida Cancer Specialists & Research Institute (FCS) will be actively participating in the Florida Society of Clinical Oncology (FLASCO) 2026 Spring Congress held in Orlando. This event is notably significant, as it revolves around the Business of Oncology Summit, where healthcare professionals come together to discuss pressing issues and developments in cancer care.

FCS's Assistant Managing Physician, Dr. David Wenk, emphasized the importance of forums like FLASCO in fostering collaboration among oncology leaders. "Events like the FLASCO Spring Congress provide an important opportunity for oncology leaders to collaborate, share insights, and explore innovative approaches that are shaping the future of cancer care," said Dr. Wenk. This proactive approach ensures that the field of oncology continuously evolves to meet patient needs effectively.

At the event, FCS’s Director of Advocacy and Policy, Dr. Richard McDonough, is set to participate as a panelist in discussions centered around shifting oncology practice models and the redefined workforce in the sector. The panel titled "From Traditional Practice Models to a Redefined Oncology Workforce" will shed light on contemporary practices in oncology. Additionally, Dr. McDonough will be hosting a reception targeting fellows and residents interested in oncology, providing crucial networking opportunities with established physicians in the field.

As cancer care dynamics evolve, Dr. McDonough stresses the need for adaptation in care delivery models. He stated, "As the oncology landscape continues to evolve, it is essential that we adapt how care is delivered, strengthening our workforce, embracing new care models, and ensuring patients continue to receive high-quality, accessible treatment.” This reflects the pressing necessity to modernize practices in response to advancements in research and technology.

FLASCO operates as a statewide non-profit organization dedicated to improving patient care through multidisciplinary efforts among oncology professionals. FCS stands as a leader in the field, having made significant contributions over its 40 years of operation. With a commitment to innovation within oncology, they have established robust clinical research programs that have dramatically transformed patient care.

FCS’s extensive clinical research capabilities provide patients with access to numerous clinical trials, establishing the institute as a forerunner in private oncology practices not only in Florida but nationwide. These clinical trials play a pivotal role in advancing oncology science, with FCS conducting more than 180 active clinical trials each year. This access often allows patients to participate in groundbreaking therapies before they reach the broader market.

The research carried out at FCS in collaboration with prominent partners such as the Sarah Cannon Research Institute (SCRI) ensures cutting-edge treatment options are available to patients close to home. Many cancer drugs that have received FDA approval were first administered through trials at FCS, making a significant impact on patient outcomes and treatment options.

FCS prides itself on its dedicated team of highly skilled physicians who tailor treatment plans according to the latest advancements in precision oncology. Their commitment not only improves patient outcomes but strengthens the overall quality of cancer care available to those in Florida. As stakeholders at FLASCO 2026 engage in conversations that shape the future of oncology, FCS is poised to lead the charge in implementing transformative changes that prioritize patient care and leverage technological advancements.

In conclusion, the participation of Florida Cancer Specialists at FLASCO 2026 represents a crucial step in the ongoing journey to redefine cancer care. Through collaboration and innovative thinking, oncology professionals continue to pave the way for a brighter future for cancer patients across the state and beyond. FCS remains at the forefront of this evolution, dedicated to delivering unmatched care and advancing the field of oncology.